PAPER Kim T, Kang DW, Salazar Fajardo JC, Jang H, Um YH, Kim S, Wang SM, Kim D, Lim HK
SEARCH RESULTS
331357 RESULTS
PAPER Orlandi F, Carlos AF, Ali F, Clark HM, Duffy JR, Utianski RL, Botha H, Machulda MM, Stephens YC, Schwarz CG, Senjem ML, Jack CR, Agosta F, Filippi M, Dickson DW, Josephs KA, Whitwell JL
Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.
Brain Commun. 2024;6(2):fcae113. Epub 2024 Apr 5 PubMed: 38660629PAPER Nozal V, Fernández-Gómez P, García-Rubia A, Martínez-González L, Cuevas EP, Carro E, Palomo V, Martínez A
Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation.
Biomed Pharmacother. 2024 Apr 24;175:116626. PubMed: 38663103PAPER Li WB, Xu LL, Wang SL, Wang YY, Pan YC, Shi LQ, Guo DS
Co-assembled Nanoparticles Towards Multi-target Combinational Therapy of Alzheimer's Disease by Making Full Use of Molecular Recognition and Self-assembly.
Adv Mater. 2024 Apr 25;:e2401918. PubMed: 38662940Robert Sobolewski
Massachusetts General HospitalCharlestown, United States
Thomas Foltynie on Diabetes Drug Shows Promise for Parkinson’s Disease
COMMENT This is an important publication, given it essentially replicates the findings of Athauda et al., who reported positive Phase 2 data of a very similar GLP-1 receptor agonist drug, exenatide, when given to patients with Parkinson’s disease (Athauda et al.,
Oscar Mailman
Pittsburgh, United States
Nazaret Gamez
Houston Methodist Research InstituteHouston, United States
Sandrine Legg
Alchemab Therapeutics
Nigel Greig on Diabetes Drug Shows Promise for Parkinson’s Disease
COMMENT It is wonderful to see a treatment strategy, proposed by my collaborators and me in 2002 in publications describing the neuroprotective/neurotrophic actions of GLP-1 receptor agonists, demonstrating efficacy in Parkinson’s disease (Perry et al., 2002; Per
PAPER Chang CW, Tan CH, Hong WP, Yu RL
GBA moderates cognitive reserve's effect on cognitive function in patients with Parkinson's disease.
J Neurol. 2024 Apr 24; PubMed: 38656622PAPER Ikeda K, Sugiura Y, Nakao H, Nakano M
Thermodynamics of oligomerization and Helix-to-sheet structural transition of amyloid β-protein on anionic phospholipid vesicles.
Biophys Chem. 2024 Apr 18;310:107248. PubMed: 38653174PAPER Mey M, Bhatta S, Suresh S, Labrador LM, Piontkivska H, Casadesus G
Therapeutic benefits of central LH receptor agonism in the APP/PS1 AD model involve trophic and immune regulation and reproductive status dependent.
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 21;:167165. PubMed: 38653355PAPER Pilotto A, Carini M, Lupini A, di Fonzo A, Monti E, Bresciani R, Padovani A, Biasiotto G
The p.Val234Met LRP10 likely pathogenic variant associated with Parkinson's disease: Possible molecular implications.
Parkinsonism Relat Disord. 2024 Apr 17;123:106973. PubMed: 38653012PAPER Zaafar D, Elghazawy NH, Hassan A, Mahmoud MY, Bakr AF, Arafa RK
Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro, in vivo and in silico studies.
Int J Biol Macromol. 2024 Apr 21;268(Pt 1):131740. PubMed: 38653428Current Filters
No filters selected